Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Intraoperative molecular imaging of lung cancer using panitumumab-IRDye800

Award Number: R01CA300061
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/07/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Intraoperative molecular imaging of lung cancer using panitumumab-IRDye800 - Project Summary/Abstract Lung cancer is the most common cause of cancer-related deaths with a five-year overall survival of 25%, and surgery is an essential treatment for early-stage disease. Surgeons must accurately localize (identify) tumors during surgery; this is difficult when tumors are small, less dense, or deep in the lung, or when using minimally invasive surgical approaches that make palpation difficult. Surgeons must ensure adequate margins (distance from the tumor to the edge of specimen), because positive or inadequate margins have devastating consequences such as added treatment and recurrence. There is a critical need for accurate tumor localization during surgery, yet current techniques rely on cumbersome equipment and expose patients to radiation, complications, and extended operative time. Intraoperative molecular imaging is an emerging technology that relies on an imaging agent—that is given intravenously and accumulates within the tumor but not adjacent tissues—and a fluorescence camera to detect the imaging signal. Intraoperative molecular imaging avoids radiation, does not cause complications such as bleeding, and can be easily integrated into the surgical workflow. Panitumumab-IRDye800 (pan800) is a new molecular imaging agent manufactured from panitumumab, an epidermal growth factor receptor (EGFR) antibody and chemotherapeutic agent, and IRDye800, a near infrared fluorescent dye. Because EGFR expression is much higher in lung cancer than adjacent normal lung tissue, pan800 is a promising imaging agent. Pan800 has several advantages over the only FDA-approved imaging agent in lung cancer, Cytalux, including ability to image squamous cell carcinoma, low adverse event rate, ability to use standard surgical cameras, and ability to image lymph nodes. The overall objective of the proposed study is to develop molecular imaging using pan800 for tumor localization of lung cancer during surgery and ex vivo. The hypothesis is that pan800 will accumulate in lung tumors but not adjacent normal lung, leading to fluorescence during surgery and high tumor-to-background ratio ex vivo. The following three aims are proposed: (1) Determine the sensitivity of pan800 molecular imaging for tumor localization during surgery for lung cancer. (2) Determine the sensitivity of pan800 molecular imaging ex vivo for tumor localization in patients who underwent surgical resection of lung cancer. (3) Examine whether molecular imaging using pan800 is better than Cytalux using precision-cut lung slices across several types of lung cancer. In Aims and 2, a phase I/II, prospective, nonrandomized clinical trial will be conducted in patients undergoing surgery for lung cancer. In Aim 3, an innovative application of PCLS will be used as a model to compare imaging agents and study rare types of lung cancer, which will guide future clinical trials. The proposed study is significant because it will transform the surgical treatment of lung cancer, improving clinical outcomes in patients with this deadly disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $626,743 )
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Detection and Diagnosis Research	000	1	7/8/2026	NEW	$626,743
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Detection and Diagnosis Research	001	1	7/16/2026	NEW	$0
														Subtotal = $626,743

Grand Total All Awards = $626,743

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Intraoperative molecular imaging of lung cancer using panitumumab-IRDye800

Award Number: R01CA300061

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/07/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer